Brief: Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
07/11/2023 13:44
Nov 7 (Reuters) - Qualigen Therapeutics Inc QLGN.O :
* QUALIGEN THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN THE
PHASE
1A CLINICAL TRIAL OF QN-302 FOR TREATMENT OF ADVANCED OR
METASTATIC SOLID TUMORS
* QUALIGEN THERAPEUTICS INC - ANTICIPATES PROVIDING AN
UPDATE ON
SAFETY AND PRELIMINARY EFFICACY OF PHASE 1A STUDY IN FIRST HALF
OF 2024
Source text for Eikon: ID:nGNXGNhBz
Further company coverage: QLGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aixcrypto Holdings
See all newsBrief: Aixcrypto - Enters Common Shares Purchase Agreement With Gold King Arthur Holding - SEC Filing
Chief Executive Officer And Director
Brief: Aixcrypto Holdings - Enters Note Purchase Agreement With CABG Acquisition Corp On May 12, 2026 - SEC Filing
Brief: Aixcrypto Holdings Reports First Quarter 2026 Results
AIxCrypto Q1 net loss widens as expenses rise